Jubilant Pharmova (JUBLPHARMA) — Announcement

📢 Key Event
USFDA approved commercial batch manufacturing on Line 3 at Spokane facility

💡 Investor Takeaway
The approval unlocks new contract manufacturing revenue and enhances Jubilant Pharmova's position in sterile injectables and ophthalmics markets.

Jubilant Pharmova announced that its USFDA-approved contract manufacturing facility in Spokane, USA, received approval for commercial batch production on Line 3, enabling sterile injectable and ophthalmic product launches in regulated markets. This milestone strengthens its contract manufacturing revenue streams and global pharma partnerships.

📄 View Original Announcement (PDF)

📊 Stock Analysis — JUBLPHARMA ✨ Ask AI About This

About Jubilant Pharmova Limited (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,469.9 Cr P/E: 40.9 ROE: 5.0% ROCE: 7.4% Div Yield: 0.55%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

💡 Ask AI about this filing

"How will this approval impact Jubilant Pharmova's contract manufacturing revenue?" "What is the revenue contribution from US contract manufacturing?" "When will products from Line 3 reach the US market?"

Ask AI Free →

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

🔥 Also filed on 23 August 2026

MEESHO Meesho Limited Board Meeting GUJTHEM Gujarat Themis Biosyn Limited Voting Results PRITI Priti International Limited Board Meeting DONEAR Donear Industries Limited Board Meeting PNC Pritish Nandy Communications Limited Voting Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd